Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Cyclosporine before PCI in Patients with Acute Myocardial Infarction

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Contributors:
      Hôpital Arnaud de Villeneuve CHU Montpellier; Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier); Les Hôpitaux Universitaires de Strasbourg (HUS); Université de Montpellier (UM); Hôpital Cardiovasculaire Louis Pradel; Hospices Civils de Lyon (HCL); Transplantation, Immunologie, Inflammation Tours (T2i); Université de Tours (UT); Service Cardiologie CHU Toulouse; Pôle Cardiovasculaire et Métabolique CHU Toulouse; Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse); Department of Cardiology (Cardio - BORDEAUX); Centre Hospitalier Universitaire de Bordeaux (CHU Bordeaux); Radiopharmaceutiques biocliniques; Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM); Service de Cardiologie CHU Rouen; CHU Rouen; Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN); Normandie Université (NU); Service de cardiologie; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard Paris; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7); Hémostase, bio-ingénierie et remodelage cardiovasculaires (LBPC (U698)); Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Institut Galilée-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM); Lipides - Nutrition - Cancer (U866) (LNC); Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA); CHU Dijon; Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon); Service de Cardiologie; Centre Hospitalier Universitaire d'Angers (CHU Angers); PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM); Laboratoire de Protection et Remodelage du Myocarde (PMRM); Université d'Angers (UA)-Université d'Angers (UA); Service de Cardiologie CHRU Nancy; Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy); Centre hospitalier de la région d'Annecy; Centre Hospitalier Privé Beauregard. (CHPB); Centre hopitalier Privé; Optimisation des régulations physiologiques (ORPHY (EA 4324)); Université de Brest (UBO)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Institut Brestois Santé Agro Matière (IBSAM); Université de Brest (UBO)-Université de Brest (UBO); Institut de Génomique Fonctionnelle (IGF); Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS); INSERM U955, équipe 3; Institut Mondor de Recherche Biomédicale (IMRB); Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12); Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Pontchaillou; Laboratoire Traitement du Signal et de l'Image (LTSI); Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM); Pôle Cardiologie Interventionnelle / Coro-scanner / IRM Cardiaque; Clinique Saint Gatien; Hôpital Louis Pradel; Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN); Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL); Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon); Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM); Cardioprotection; Université Claude Bernard Lyon 1 (UCBL); Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)
    • Publication Information:
      CCSD
      Massachusetts Medical Society
    • Publication Date:
      2015
    • Collection:
      Université de Bourgogne (UB): HAL
    • Abstract:
      International audience ; BACKGROUND: Experimental and clinical evidence suggests that cyclosporine may attenuate reperfusion injury and reduce myocardial infarct size. We aimed to test whether cyclosporine would improve clinical outcomes and prevent adverse left ventricular remodeling. METHODS: In a multicenter, double-blind, randomized trial, we assigned 970 patients with an acute anterior ST-segment elevation myocardial infarction (STEMI) who were undergoing percutaneous coronary intervention (PCI) within 12 hours after symptom onset and who had complete occlusion of the culprit coronary artery to receive a bolus injection of cyclosporine (administered intravenously at a dose of 2.5 mg per kilogram of body weight) or matching placebo before coronary recanalization. The primary outcome was a composite of death from any cause, worsening of heart failure during the initial hospitalization, rehospitalization for heart failure, or adverse left ventricular remodeling at 1 year. Adverse left ventricular remodeling was defined as an increase of 15% or more in the left ventricular end-diastolic volume. RESULTS: A total of 395 patients in the cyclosporine group and 396 in the placebo group received the assigned study drug and had data that could be evaluated for the primary outcome at 1 year. The rate of the primary outcome was 59.0% in the cyclosporine group and 58.1% in the control group (odds ratio, 1.04; 95% confidence interval [CI], 0.78 to 1.39; P=0.77). Cyclosporine did not reduce the incidence of the separate clinical components of the primary outcome or other events, including recurrent infarction, unstable angina, and stroke. No significant difference in the safety profile was observed between the two treatment groups. CONCLUSIONS: In patients with anterior STEMI who had been referred for primary PCI, intravenous cyclosporine did not result in better clinical outcomes than those with placebo and did not prevent adverse left ventricular remodeling at 1 year. (Funded by the French Ministry of Health and ...
    • Relation:
      info:eu-repo/semantics/altIdentifier/pmid/26321103; PUBMED: 26321103
    • Accession Number:
      10.1056/NEJMoa1505489
    • Online Access:
      https://univ-rennes.hal.science/hal-01260566
      https://univ-rennes.hal.science/hal-01260566v1/document
      https://univ-rennes.hal.science/hal-01260566v1/file/nejmoa1505489.pdf
      https://doi.org/10.1056/NEJMoa1505489
    • Rights:
      info:eu-repo/semantics/OpenAccess
    • Accession Number:
      edsbas.C5DB86D7